6/5/2014 9:09:16 AM
CHICAGO, June 4, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the Phase 3 data from its DISCOVER program evaluating dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults was the subject of an article published in the latest edition of the New England Journal of Medicine (NEJM), "Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection." The complete article is now available online to subscribers at www.nejm.org and will appear in the June 5th print edition. The article highlights the benefits of dalbavancin and its potential to change the treatment paradigm for ABSSSI patients.
Help employers find you! Check out all the jobs and post your resume.
comments powered by